INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS

Bronchial asthma (BA) is the most widespread chronic inflammatory disease. Since BA is associated with a systemic inflammation state, a comprehensive study of its effect in this disease, and influence of pathogenetic therapy should be performed, by studying the whole blood cytokine status of the pat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: D. A. Serov, D. S. Kabanov, N. I. Kosyakova, I. R. Prokhorenko
Formato: article
Lenguaje:RU
Publicado: SPb RAACI 2019
Materias:
Acceso en línea:https://doaj.org/article/8e628d55c62342608b8a516fe1f80dbf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:8e628d55c62342608b8a516fe1f80dbf
record_format dspace
institution DOAJ
collection DOAJ
language RU
topic bronchial asthma
innate immunity
blood leukocyte
human
lipopolysaccharides
cytokine production
Immunologic diseases. Allergy
RC581-607
spellingShingle bronchial asthma
innate immunity
blood leukocyte
human
lipopolysaccharides
cytokine production
Immunologic diseases. Allergy
RC581-607
D. A. Serov
D. S. Kabanov
N. I. Kosyakova
I. R. Prokhorenko
INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS
description Bronchial asthma (BA) is the most widespread chronic inflammatory disease. Since BA is associated with a systemic inflammation state, a comprehensive study of its effect in this disease, and influence of pathogenetic therapy should be performed, by studying the whole blood cytokine status of the patients suffering with BA. The cells from respiratory tract in acute-phase BA patients may produce pro-, as well as anti-inflammatory mediators. The anti-inflammatory mediators are able to suppress activity of immune cells in peripheral blood. Thus, the aim of present study was to evaluate eventual inflammation-associated and functional activity of immune cells from the patients’ peripheral blood in BA and following appropriate therapy. Bacterial lipopolysaccharide (LPS) a classical pro-inflammatory agent. We have studied an LPSinduced cytokine-induced ex vivo secretion model by peripheral blood immune cells, as a relevant test for their functional activity. The LPS-induced responses of whole blood cells from patients with proven BA diagnosis have been studied at pre-treatment time points, and following two weeks of basic anti-inflammatory therapy. According to clinical indications, the antagonists of CysLTR1, or combinations of glucocorticosteroids and β-adrenoreceptor agonists were administered by inhalation to BA patients. LPS-induced production of TNFα, IL-6, IL-8 (at 6 h) and IFNγ, IL-17A or IL-1β (at 24 h) by whole blood cells from BA patients or healthy volunteers has been assessed by ELISA technique. The cytokine production from non-stimulated whole blood cells from BA patients and healthy volunteers were used as the baseline control. IL-4 concentrations in plasma of BA patients and healthy volunteers were also measured. We have shown a decrease of IL-6 production in control blood samples from BA patients after two weeks of therapy. This may indicate the attenuation of the observed inflammatory process. The therapy applied did not influence the background levels and LPS-induced secretion of IL-1β, IL-1ra, IFNγ, and IL-8 in whole blood samples from BA patients. IL-4 plasma levels in BA patients were not changed after two weeks of therapy. It has been shown that whole blood from BA patients produced less TNFα and IL-8, both in control samples, and during their response to LPS, than the values obtained in healthy volunteers. These findings are in agreement with a notion that BA causes partial depression of innate immune cells activity. The increased LPS-induced TNFα secretion by the whole blood cells from BA patients has been observed following two weeks of basic anti-inflammatory therapy. We suggest that the increased LPS-induced TNFα secretion could be explained by partial restoration of peripheral blood immune cell activity associated with anti-inflammatory BA therapy. To elucidate the mechanism of increased LPS-induced TNFα secretion, we have estimated whole blood concentration of soluble CD14 (sCD14) in BA patients. No significant differences between sCD14 concentrations have been found. Obtained result presume existence of sCD14-independent mechanism of TNFα regulation by whole blood cells in response on LPS which may occur during anti-inflammatory therapy of BA. We suppose that basic anti-inflammatory therapy of BA does not simply reduce IL-6 concentration in peripheral blood, but may also partially restore the activity of innate immune cells in BA patients.
format article
author D. A. Serov
D. S. Kabanov
N. I. Kosyakova
I. R. Prokhorenko
author_facet D. A. Serov
D. S. Kabanov
N. I. Kosyakova
I. R. Prokhorenko
author_sort D. A. Serov
title INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS
title_short INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS
title_full INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS
title_fullStr INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS
title_full_unstemmed INFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS
title_sort influence of therapy upon lps-induced cytokine secretion by the blood-derived innate immunity cells of the bronchial asthma patients
publisher SPb RAACI
publishDate 2019
url https://doaj.org/article/8e628d55c62342608b8a516fe1f80dbf
work_keys_str_mv AT daserov influenceoftherapyuponlpsinducedcytokinesecretionbythebloodderivedinnateimmunitycellsofthebronchialasthmapatients
AT dskabanov influenceoftherapyuponlpsinducedcytokinesecretionbythebloodderivedinnateimmunitycellsofthebronchialasthmapatients
AT nikosyakova influenceoftherapyuponlpsinducedcytokinesecretionbythebloodderivedinnateimmunitycellsofthebronchialasthmapatients
AT irprokhorenko influenceoftherapyuponlpsinducedcytokinesecretionbythebloodderivedinnateimmunitycellsofthebronchialasthmapatients
_version_ 1718422365606510592
spelling oai:doaj.org-article:8e628d55c62342608b8a516fe1f80dbf2021-11-18T08:03:48ZINFLUENCE OF THERAPY UPON LPS-INDUCED CYTOKINE SECRETION BY THE BLOOD-DERIVED INNATE IMMUNITY CELLS OF THE BRONCHIAL ASTHMA PATIENTS1563-06252313-741X10.15789/1563-0625-2019-4-789-796https://doaj.org/article/8e628d55c62342608b8a516fe1f80dbf2019-10-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1884https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XBronchial asthma (BA) is the most widespread chronic inflammatory disease. Since BA is associated with a systemic inflammation state, a comprehensive study of its effect in this disease, and influence of pathogenetic therapy should be performed, by studying the whole blood cytokine status of the patients suffering with BA. The cells from respiratory tract in acute-phase BA patients may produce pro-, as well as anti-inflammatory mediators. The anti-inflammatory mediators are able to suppress activity of immune cells in peripheral blood. Thus, the aim of present study was to evaluate eventual inflammation-associated and functional activity of immune cells from the patients’ peripheral blood in BA and following appropriate therapy. Bacterial lipopolysaccharide (LPS) a classical pro-inflammatory agent. We have studied an LPSinduced cytokine-induced ex vivo secretion model by peripheral blood immune cells, as a relevant test for their functional activity. The LPS-induced responses of whole blood cells from patients with proven BA diagnosis have been studied at pre-treatment time points, and following two weeks of basic anti-inflammatory therapy. According to clinical indications, the antagonists of CysLTR1, or combinations of glucocorticosteroids and β-adrenoreceptor agonists were administered by inhalation to BA patients. LPS-induced production of TNFα, IL-6, IL-8 (at 6 h) and IFNγ, IL-17A or IL-1β (at 24 h) by whole blood cells from BA patients or healthy volunteers has been assessed by ELISA technique. The cytokine production from non-stimulated whole blood cells from BA patients and healthy volunteers were used as the baseline control. IL-4 concentrations in plasma of BA patients and healthy volunteers were also measured. We have shown a decrease of IL-6 production in control blood samples from BA patients after two weeks of therapy. This may indicate the attenuation of the observed inflammatory process. The therapy applied did not influence the background levels and LPS-induced secretion of IL-1β, IL-1ra, IFNγ, and IL-8 in whole blood samples from BA patients. IL-4 plasma levels in BA patients were not changed after two weeks of therapy. It has been shown that whole blood from BA patients produced less TNFα and IL-8, both in control samples, and during their response to LPS, than the values obtained in healthy volunteers. These findings are in agreement with a notion that BA causes partial depression of innate immune cells activity. The increased LPS-induced TNFα secretion by the whole blood cells from BA patients has been observed following two weeks of basic anti-inflammatory therapy. We suggest that the increased LPS-induced TNFα secretion could be explained by partial restoration of peripheral blood immune cell activity associated with anti-inflammatory BA therapy. To elucidate the mechanism of increased LPS-induced TNFα secretion, we have estimated whole blood concentration of soluble CD14 (sCD14) in BA patients. No significant differences between sCD14 concentrations have been found. Obtained result presume existence of sCD14-independent mechanism of TNFα regulation by whole blood cells in response on LPS which may occur during anti-inflammatory therapy of BA. We suppose that basic anti-inflammatory therapy of BA does not simply reduce IL-6 concentration in peripheral blood, but may also partially restore the activity of innate immune cells in BA patients.D. A. SerovD. S. KabanovN. I. KosyakovaI. R. ProkhorenkoSPb RAACIarticlebronchial asthmainnate immunityblood leukocytehumanlipopolysaccharidescytokine productionImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 21, Iss 4, Pp 789-796 (2019)